Biomarkers and Antibody Development for Heart Failure

Biomarkers that can be measured and evaluated as reliable indicators of pathogenic processes and pharmacological response to therapeutic intervention are of great value for early diagnosis of diseases, risk stratification, prediction of mortality, and therapeutic monitoring. The detection of biomarkers in biological samples usually depends on the use of sensitive immunoassays. High-quality antibodies are of utmost importance for the development of highly sensitive immunoassays.

With abundant experience in antibody development and advanced technologies, Creative Biolabs is proud to offer customized antibody development services targeting various biomarkers of heart failure for in vitro diagnostic (IVD) applications. Here, we focus on heart failure and its potential diagnostic biomarkers.

Introduction of Heart Failure

Heart failure (HF) is one of the leading causes of death in both the US and worldwide, causing a significant burden on health care systems. Clinically, HF is a complex disease process that can result from a variety of conditions preventing the left ventricle from properly filling and ejecting blood. Symptoms of HF commonly include shortness of breath, limited ability to exercise, excessive tiredness, and swelling in ankles and legs. It is commonly caused by different coronary artery diseases (e.g., myocardial infarction, high blood pressure) and bad life habits (e.g., excess alcohol use). Other diseases, such as obesity, kidney failure, and anemia, may have symptoms similar to HF.

The diagnosis of HF is often made based on different techniques and tests, including physical examination, echocardiogram, chest X-rays, electrocardiogram, angiography, and blood tests. The treatment is based on the different severity and cause of this disease. Common treatment strategies include both lifestyle modifications and drugs.

Schematic representation of the release of various biomarkers from organs in patients with HF.Fig.1 Schematic representation of the release of various biomarkers from organs in patients with HF. (Iqbal, N., 2012)

The Application of Biomarkers for HF Diagnosis

Biomarkers, with their objectivity and widespread availability, provide a low-cost, low-risk, and quick turnaround method to confirm or exclude an HF diagnosis, help to establish prognosis in the diagnosis, and more fundamentally, may provide substantial information on the complex pathophysiology that defines the syndrome of HF. A large number of biomarkers have been developed that reflect different pathologies of HF, including cardiac myocyte strain, inflammatory processes, neurohormonal activation, pneumonia, etc. In recent years, significant effort has been placed on biomarker research, leading to the emergence of several promising novel cardiac biomarkers for HF diagnosis and risk stratification.

IVD Antibody Development Services Provided by Creative Biolabs

Antibodies have become a critical component of many immunodiagnostic assays. With our integrated antibody development, engineering, and characterization platform, Creative Biolabs offers contract research services to develop high-quality IVD antibodies against multiple HF disease markers, with low cross-reactivity and high sensitivity. Moreover, we can validate the antibodies for different immunoassays, including ELISA, lateral flow, IHC, and so on. We can start from scratch or with provided antibodies to commercial IVD kits.

Please feel free to contact us for more information and a formal quote.

Our services target various HF biomarkers, including but not limited to:


Reference

  1. Iqbal, N., 2012. “Cardiac biomarkers: new tools for heart failure management.” Cardiovascular diagnosis and therapy. 2(2), p.147.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.